Additional value of 16α-[ 18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [ 18F]fluorodeoxyglucose PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 10, 2011, Pages 1824-1831

  Yoshida, Yoshio ^a   Kiyono, Yasushi ^a   Tsujikawa, Tetsuya ^a   Kurokawa, Tetsuji ^a   Okazawa, Hidehiko ^a   Kotsuji, Fumikazu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

FDG uptake; Glucose metabolism; Leiomyoma; Oestrogen receptor imaging; PET; Uterine sarcoma

Indexed keywords

16ALPHA FLUORINE 18 FLOURO ESTRADIOL; ESTRADIOL; ESTROGEN RECEPTOR; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; LEIOMYOMA; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; ULTRASOUND; UTERUS SARCOMA;

ADULT; AGED; BIOLOGICAL TRANSPORT; DIAGNOSIS, DIFFERENTIAL; ESTRADIOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LEIOMYOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; SARCOMA; UTERINE NEOPLASMS;

EID: 80455164716     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1851-8     Document Type: Article

References (31)

1. Adams Hillard PJ. Benign disease of the female reproductive tract. In: Berek JS, editor. Berek & Novak's gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 431-504.
2. Sutton GP, Stehman FB, Michael H, Young PC, Ehrlich CE. Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol 1986;68:709-14. (Pubitemid 16005591)
3. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol 2009;10:1188-98.
4. Milman D, Zalel Y, Biran H, Open M, Caspi B, Hagay Z, et al. Unsuspected uterine leiomyosarcoma discovered during treatment with a gonadotropin-releasing hormone analogue: a case report and literature review. Eur J Obstet Gynecol Reprod Biol 1998;76:237-40. (Pubitemid 28031920)
5. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004;104:393-406. (Pubitemid 40458890)
6. Parker WH. Uterine myomas: management. Fertil Steril 2007;88:255-71. (Pubitemid 47212168)
7. Schwartz LB, Zawin M, Carcangiu ML, Lange R, McCarthy S. Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata? Fertil Steril 1998;70:580-7. (Pubitemid 28435653)
8. Sahdev A, Sohaib SA, Jacobs I, Shepherd JH, Oram DH, Reznek RH. MR imaging of uterine sarcomas. AJR Am J Roentgenol 2001;177:1307-11. (Pubitemid 33081470)
9. Kido A, Togashi K, Koyama T, Yamaoka T, Fujiwara T, Fujii S. Diffusely enlarged uterus: evaluation with MR imaging. Radiographics 2003;23:1423-39. (Pubitemid 37487519)
10. Tanaka YO, Nishida M, Tsunoda H, Okamoto Y, Yoshikawa H. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings. J Magn Reson Imaging 2004;20:998-1007. (Pubitemid 39577902)
11. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32. (Pubitemid 38552885)
12. Yoshida Y, Kurokawa T, Sawamura Y, Shinagawa A, Tsujikawa T, Okazawa H, et al. Comparison of 18F-FDG PET and MRI in assessment of uterine smooth muscle tumors. J Nucl Med 2008;49:708-12. (Pubitemid 351717534)
13. Kitajima K, Murakami K, Kaji Y, Sugimura K. Spectrum of FDG PET/CT findings of uterine tumors. AJR Am J Roentgenol 2010;195:737-43.
14. Tsujikawa T, Yoshida Y, Mori T, Kurokawa T, Fujibayashi Y, Kotsuji F, et al. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta- estradiol and 18F fluorodeoxyglucose PET-initial experience. Radiology 2008;248:599-605.
15. Mori T, Kasamatsu S, Mosdzianowski C, Welch MJ, Yonekura Y, Fujibayashi Y. Automatic synthesis of 16 alpha-[(18) F]fluoro-17beta-estradiol using a cassette-type [(18) F]fluorodeoxyglucose synthesizer. Nucl Med Biol 2006;33:281-6.
16. Tsujikawa T, Yoshida Y, Kudo T, Kiyono Y, Kurokawa T, Kobayashi M, et al. Functional images reflect aggressiveness of endometrial cancer: estrogen receptor expression combined with 18FDG PET. J Nucl Med 2009;50:1598-604.
17. Gompel C, Silverberg SG Pathology in gynecology and obstetrics. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1994. p. 163-283.
18. Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res 2003;23:729-32. (Pubitemid 36358480)
19. Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004;101:1455-62. (Pubitemid 39180402)
20. Zhai YL, Kobayashi Y, Mori A, Orii A, Nikaido T, Konishi I, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999;18:20-8. (Pubitemid 29028841)
21. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001;32:984-7. (Pubitemid 32911322)
22. Ioffe YJ, Li AJ, Walsh CS, Karlan BY Leuchter R, Forscher C, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol 2009;115:466-71.
23. Uchida T, Nakakawaji K, Sakamoto J, Kojima H, Murakami H, Kato J, et al. The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas: report of a case. Surg Today 1996;26:138-41. (Pubitemid 26088328)
24. Tsujikawa T, Yoshida Y Kiyono Y Kurokawa T, Kudo T, Fujibayashi Y et al. Functional oestrogen receptor alpha imaging in endometrial carcinoma using 16alpha-[(18) F]fluoro-17betaoestradiol PET. Eur J Nucl Med Mol Imaging 2011;38(1):37-45.
25. Conneely OM, Lydon JP, De Mayo F, O'Malley BW. Reproductive functions of the progesterone receptor. J Soc Gynecol Investig 2000;7:S25-32.
26. Zhu XQ, Shi YF, Cheng XD, Zhao CL, Wu YZ. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol 2004;92:71-9.
27. Kir G, Cetiner H, Karateke A, Gurbuz A, Bulbul D. Utility of MIB-1 and estrogen and progesterone receptor in distinguishing between endometrial stromal sarcomas and endometrial stromal nodules, highly cellular leiomyomas. Int J Gynecol Cancer 2005;15:337-42. (Pubitemid 40396975)
28. Policarpio-Nicolas ML, Cathro HP, Kerr SE, Stelow EB. Cytomorphologic features of low-grade endometrial stromal sarcoma. Am J Clin Pathol 2007;128:265-71. (Pubitemid 47262625)
29. Gregory S, John K, Aaron W, Carmen T. Corpus: mesenchymal tumors. In: Barakat RR, editor. Principles and practice of gynecologic oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 733-61.
30. Oda K, Okada S, Nei T, Shirai T, Takahashi M, Sano Y et al. Cytodiagnostic problems in uterine sarcoma. Analysis according to a novel classification of tumor growth types. Acta Cytol 2004;48:181-6. (Pubitemid 38381103)
31. Tsuchida T, Okazawa H, Mori T, Kobayashi M, Yoshida Y Fujibayashi Y et al. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET-influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol 2007;34:205-10. (Pubitemid 46241898)